Immune Intervention for Type 1 Diabetes, 2013–2014
نویسندگان
چکیده
منابع مشابه
Biomarkers for immune intervention trials in type 1 diabetes.
After many efforts to improve and standardize assays for detecting immune biomarkers in type 1 diabetes (T1D), methods to identify and monitor such correlates of insulitis are coming of age. The ultimate goal is to use these correlates to predict disease progression before onset and regression following therapeutic intervention, which would allow performing smaller and shorter pilot clinical tr...
متن کاملImmune Intervention in Type I Diabetes Mellitus
In many countries Type 1 diabetes [T1D] is the most common life-threatening disease in chil‐ dren, and nobody can be cured. For long time the incidence has increased all over the world [1]. The disease causes serious morbidity and increased mortality [2,3] in spite of an intensive treatment with multiple daily injections of insulin, adapted to regular meals with suitable content based on self-m...
متن کاملFuture intervention trials in type 1 diabetes.
The recently completed trials using insulin (U.S.) and nicotinamide (Europe) were not effective in preventing type 1 diabetes (1,2), but they leave an important legacy of goodwill among their collaborators and expertise in the conduct of such trials and a network through which more may be carried out. A commentary on the trials has recently been published (3), and its authors urge “a different ...
متن کاملAltered Immune Regulation in Type 1 Diabetes
Research in genetics and immunology was going on separate strands for a long time. Type 1 diabetes mellitus might not be characterized with a single pathogenetic factor. It develops when a susceptible individual is exposed to potential triggers in a given sequence and timeframe that eventually disarranges the fine-tuned immune mechanisms that keep autoimmunity under control in health. Genomewid...
متن کاملChallenges in developing endpoints for type 1 diabetes intervention studies.
Development of efficient and safe intervention strategies for preserving and/or restoring endogenous insulin production in type 1 diabetes has encountered a wide range of challenges, including lack of standardized trial protocols and of consensus on appropriate efficacy endpoints. For the greatest part, difficulties resided in choosing the most suitable assay(s) and parameter(s) to assess the b...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes Technology & Therapeutics
سال: 2015
ISSN: 1520-9156,1557-8593
DOI: 10.1089/dia.2015.1510